CIK 0001984086 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Septerna, Inc.
Sign in to watch- Ticker
- SEPN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 843891440
- Phone
- 650-338-3533
- Business address
- 250 EAST GRAND AVENUE, SUITE 65, SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $4,210,085
- in 3 filings, $4.2M under 10b5-1 plans
Net −$4,210,085. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-11-11 | Ezekowitz Alan Director | Sale 10b5-1 | −6,939 | $46.01 | $319K | 110,481 |
| 2026-11-11 | Ezekowitz Alan Director | Sale 10b5-1 | −13,201 | $47.01 | $621K | 97,280 |
| 2026-11-11 | Ezekowitz Alan Director | Sale 10b5-1 | −22,865 | $47.78 | $1.1M | 74,415 |
| 2026-11-11 | Ezekowitz Alan Director | Sale 10b5-1 | −31,572 | $48.70 | $1.5M | 42,843 |
| 2026-11-11 | Ezekowitz Alan Director | Sale 10b5-1 | −4,175 | $49.65 | $207K | 38,668 |
| 2026-11-11 | Ezekowitz Alan Director | Sale 10b5-1 | −2,013 | $50.90 | $102K | 36,655 |
| 2026-11-11 | Ezekowitz Alan Director | Sale 10b5-1 | −1,055 | $51.90 | $55K | 35,600 |
| 2026-10-15 | Bhatt Elizabeth President and COO | Option exercise 10b5-1 | +4,000 | $6.81 | $27K | 178,209 |
| 2026-10-15 | Bhatt Elizabeth President and COO | Sale 10b5-1 | −1,094 | $36.87 | $40K | 177,115 |
| 2026-10-15 | Bhatt Elizabeth President and COO | Sale 10b5-1 | −2,906 | $37.61 | $109K | 174,209 |
| 2026-10-15 | Bhatt Elizabeth President and COO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −4,000 | 58,230 | ||
| 2026-09-08 | Patni Rajiv Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +275,000 | 275,000 | ||
| 2026-09-01 | Long Daniel D. SVP, Drug Discovery | Option exercise 10b5-1 | +3,333 | $2.76 | $9K | 99,745 |
| 2026-09-01 | Long Daniel D. SVP, Drug Discovery | Sale 10b5-1 | −3,333 | $37.83 | $126K | 96,412 |
| 2026-09-01 | Long Daniel D. SVP, Drug Discovery | Option exercise · Stock Option (Right to Buy) 10b5-1 | −3,333 | 9,085 | ||
| 2026-08-12 | RA CAPITAL MANAGEMENT, L.P. Director | Sale | −746,500 | $42.50 | $31.7M | 4,777,415 |
| 2026-08-12 | RA CAPITAL MANAGEMENT, L.P. Director | Sale | −746,500 | $42.50 | $31.7M | 725,443 |
| 2026-08-12 | Third Rock Ventures V, L.P. 10% owner | Sale 10b5-1 | +147,059 | $50.27 | $7.4M | 6,068,532 |
| 2026-08-12 | Third Rock Ventures V, L.P. 10% owner | Sale 10b5-1 | +141 | $51.08 | $7K | 6,068,391 |
| 2026-08-11 | Bhatt Elizabeth President and COO | Option exercise 10b5-1 | +18,681 | $6.81 | $127K | 192,890 |
Page 1 of 8 · 148 trades